相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation
V. Kohl et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene
Eleftheria Mavridou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration
Verena Hafner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis
Eleftheria Mavridou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients
Claudia Michael et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Azole Binding Properties of Candida albicans Sterol 14-α Demethylase (CaCYP51)
Andrew G. S. Warrilow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview
Hans-Peter Lipp
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Voriconazole Pharmacokinetics and Pharmacodynamics in Children
Michael Neely et al.
CLINICAL INFECTIOUS DISEASES (2010)
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Yanjun Li et al.
CLINICAL PHARMACOKINETICS (2010)
Exposure-Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma
S. H. Jang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Epidemiology of Invasive Mycoses in North America
Michael A. Pfaller et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2010)
The Epidemiology of Obesity
Dang M. Nguyen et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2010)
Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipients
Elizabeth Dodds-Ashley
PHARMACOTHERAPY (2010)
Therapy for fungal diseases: opportunities and priorities
David W. Denning et al.
TRENDS IN MICROBIOLOGY (2010)
Antifungal Therapeutic Drug Monitoring
Russell E. Lewis
CURRENT FUNGAL INFECTION REPORTS (2010)
Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers
Gopal Krishna et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications
David Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy Volunteers
Gopal Krishna et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
Ina Scholz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Drug-Drug Interactions of Triazole Antifungal Agents in Multimorbid Patients and Implications for Patient Care
Yasmine Nivoix et al.
CURRENT DRUG METABOLISM (2009)
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
Guo Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes
Kazuaki Matsumoto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Johanna Weiss et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Association of fluconazole pharmacodynamics with mortality in patients with candidemia
John W. Baddley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Treatment of scedosporiosis with voriconazole: Clinical experience with 107 patients
Peter Troke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects - Two prospective, multicentre, open-label, parallel-group volunteer studies
Samantha Abel et al.
CLINICAL DRUG INVESTIGATION (2008)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
The effect of gastric acid on the absorption of posaconazole
Rupali Jain et al.
CLINICAL INFECTIOUS DISEASES (2008)
Treatment-related risk factors for hospital mortality in Candida bloodstream infections
Andrew J. Labelle et al.
CRITICAL CARE MEDICINE (2008)
Current options in antifungal pharmacotherapy
John Mohr et al.
PHARMACOTHERAPY (2008)
Torsades de Pointes ventricular tachycardia in a pediatric patient treated with fluconazole
Jesse J. Esch et al.
PEDIATRIC CARDIOLOGY (2008)
Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus
Jane M. Prosser et al.
INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE (2008)
Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease
Gopal Krishna et al.
PHARMACOTHERAPY (2007)
Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines
Kevin W. Garey et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Inherited long QT syndrome revealed by antifungals drug-drug interaction
C. Eiden et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2007)
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Steve Trifilio et al.
CANCER (2007)
Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men
G. Krishna et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
Oliver A. Cornely et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
Andrew J. Ullmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2007)
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods
Andres Pascual et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports
Dan Justo et al.
MYCOSES (2006)
Pharmacokinetics and pharmacodynamics of antifungals
David Andes
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2006)
Pharmacology of systemic antifungal agents
Elizabeth S. Dodds Ashley et al.
CLINICAL INFECTIOUS DISEASES (2006)
Long QTc interval and torsade de pointes caused by fluconazole
C. Phu Pharn et al.
ANNALS OF PHARMACOTHERAPY (2006)
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients
Paul O. Gubbins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia
Hiro Tatetsu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers
A Sansone-Parsons et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Voriconazole therapeutic drug monitoring
J Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Correlation of MIC with outcome for Candida species tested against voriconazole:: Analysis and proposal for interpretive breakpoints
MA Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection
AJ Ullmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities
K Tan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Activity of posaconazole in the treatment of central nervous system fungal infections
P Pitisuttithum et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia
CJ Clancy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
S Trifilio et al.
BONE MARROW TRANSPLANTATION (2005)
In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
RE Lewis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Oral bioavailability of posaconazole in fasted healthy subjects - Comparison between three regimens and basis for clinical dosage recommendations
F Ezzet et al.
CLINICAL PHARMACOKINETICS (2005)
Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism
N Picard et al.
DRUG METABOLISM AND DISPOSITION (2005)
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study
D Wexler et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men
R Courtney et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)
A Ghosal et al.
DRUG METABOLISM AND DISPOSITION (2004)
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults
R Courtney et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection
F Barchiesi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Disposition of posaconazole following single-dose oral administration in healthy subjects
P Krieter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Clinical utility of antifungal pharmacokinetics and pharmacodynamics
D Andes
CURRENT OPINION IN INFECTIOUS DISEASES (2004)
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Clinical pharmacodynamics of antifungals
D Andes
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2003)
In vivo pharmacodynamics of a new triazole, ravulconazole, in a murine candidiasis model
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Clinical pharmacology of antifungal compounds
AH Groll et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2003)
Effect of food on the pharmacokinetics of multiple-dose oral voriconazole
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Histamine H-2-receptor antagonists have no clinicafly significant effect on the steady-state pharmacokinetics of voriconazole
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
DW Denning et al.
CLINICAL INFECTIOUS DISEASES (2002)
Clinical significance of the cytochrome P4502C19 genetic polymorphism
Z Desta et al.
CLINICAL PHARMACOKINETICS (2002)
Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients
C Csajka et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia
R Petraitiene et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature
A Espinel-Ingroff et al.
MYCOPATHOLOGIA (2001)
Interactions between triazoles and amphotericin B against Cryptococcus neoformans
F Barchiesi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
分享论文
